{"title":"巴鲁UNDATA医院新冠肺炎患者用药模式","authors":"A. Rumi, N. Ambianti, Desti Sulistiani Arbi","doi":"10.20473/jaki.v10i1.2022.99-110","DOIUrl":null,"url":null,"abstract":"Background: Covid-19 cases had drastically increased. Little therapy has been formulated to respond to the situation. Covid-19 symptoms in Indonesia are divided into four classes: asymptomatic, mild, moderate, and severe.\nAims: This study aims to illustrate the pattern of drug use in Covid-19 patients at Undata Palu Hospital.\nMethods: This study is a type of cross-sectional descriptive study using a cross-sectional design and collecting data retrospectively from medical records at Undata Hospital Palu in 2020.\nResults: In 2020, 186 patients were confirmed positive for Covid-19. There were 95 female patients (51.9%) and 50 patients at the age of 46-55 years (27.3%). The severe symptoms happened to 109 patients (59.6%). The most common clinical manifestation was cough in 127 patients (23.3%). The most common comorbidity was pneumonia (30.8%). The most widely used primary therapy was the antibiotic azithromycin applied to 155 patients (30.0%), and the most widely used supportive therapy was vitamin C among 141 patients (20.1%). Oseltamivir antiviral therapy was administered to 132 patients (25.6%) and remdesivir to 34 patients (6.6%).\nConclusion: Covid-19 patients were mostly treated with antibiotic therapy (41.5%), antiviral therapy (32.2%), antimalarial therapy (15.7%), and corticosteroid therapy (10.7%). As many as 132 patients took oseltamivir, and 34 patients took remdesivir. However, for now, oseltamivir is no longer used.","PeriodicalId":32968,"journal":{"name":"Jurnal Administrasi Kesehatan Indonesia","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PATTERNS OF MEDICINE USE FOR COVID-19 PATIENTS AT UNDATA HOSPITAL PALU\",\"authors\":\"A. Rumi, N. Ambianti, Desti Sulistiani Arbi\",\"doi\":\"10.20473/jaki.v10i1.2022.99-110\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Covid-19 cases had drastically increased. Little therapy has been formulated to respond to the situation. Covid-19 symptoms in Indonesia are divided into four classes: asymptomatic, mild, moderate, and severe.\\nAims: This study aims to illustrate the pattern of drug use in Covid-19 patients at Undata Palu Hospital.\\nMethods: This study is a type of cross-sectional descriptive study using a cross-sectional design and collecting data retrospectively from medical records at Undata Hospital Palu in 2020.\\nResults: In 2020, 186 patients were confirmed positive for Covid-19. There were 95 female patients (51.9%) and 50 patients at the age of 46-55 years (27.3%). The severe symptoms happened to 109 patients (59.6%). The most common clinical manifestation was cough in 127 patients (23.3%). The most common comorbidity was pneumonia (30.8%). The most widely used primary therapy was the antibiotic azithromycin applied to 155 patients (30.0%), and the most widely used supportive therapy was vitamin C among 141 patients (20.1%). Oseltamivir antiviral therapy was administered to 132 patients (25.6%) and remdesivir to 34 patients (6.6%).\\nConclusion: Covid-19 patients were mostly treated with antibiotic therapy (41.5%), antiviral therapy (32.2%), antimalarial therapy (15.7%), and corticosteroid therapy (10.7%). As many as 132 patients took oseltamivir, and 34 patients took remdesivir. However, for now, oseltamivir is no longer used.\",\"PeriodicalId\":32968,\"journal\":{\"name\":\"Jurnal Administrasi Kesehatan Indonesia\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Jurnal Administrasi Kesehatan Indonesia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.20473/jaki.v10i1.2022.99-110\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jurnal Administrasi Kesehatan Indonesia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20473/jaki.v10i1.2022.99-110","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
PATTERNS OF MEDICINE USE FOR COVID-19 PATIENTS AT UNDATA HOSPITAL PALU
Background: Covid-19 cases had drastically increased. Little therapy has been formulated to respond to the situation. Covid-19 symptoms in Indonesia are divided into four classes: asymptomatic, mild, moderate, and severe.
Aims: This study aims to illustrate the pattern of drug use in Covid-19 patients at Undata Palu Hospital.
Methods: This study is a type of cross-sectional descriptive study using a cross-sectional design and collecting data retrospectively from medical records at Undata Hospital Palu in 2020.
Results: In 2020, 186 patients were confirmed positive for Covid-19. There were 95 female patients (51.9%) and 50 patients at the age of 46-55 years (27.3%). The severe symptoms happened to 109 patients (59.6%). The most common clinical manifestation was cough in 127 patients (23.3%). The most common comorbidity was pneumonia (30.8%). The most widely used primary therapy was the antibiotic azithromycin applied to 155 patients (30.0%), and the most widely used supportive therapy was vitamin C among 141 patients (20.1%). Oseltamivir antiviral therapy was administered to 132 patients (25.6%) and remdesivir to 34 patients (6.6%).
Conclusion: Covid-19 patients were mostly treated with antibiotic therapy (41.5%), antiviral therapy (32.2%), antimalarial therapy (15.7%), and corticosteroid therapy (10.7%). As many as 132 patients took oseltamivir, and 34 patients took remdesivir. However, for now, oseltamivir is no longer used.